During the last session, Unity Biotechnology Inc (NASDAQ:UBX)’s traded shares were 0.39 million, with the beta value of the company hitting 0.78. At the end of the trading day, the stock’s price was $1.28, reflecting an intraday gain of 12.28% or $0.14. The 52-week high for the UBX share is $2.02, that puts it down -57.81 from that peak though still a striking 26.56% gain since the share price plummeted to a 52-week low of $0.94. The company’s market capitalization is $21.57M, and the average intraday trading volume over the past 10 days was 0.13 million shares, and the average trade volume was 79.51K shares over the past three months.
Unity Biotechnology Inc (UBX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. UBX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Unity Biotechnology Inc (NASDAQ:UBX) trade information
Unity Biotechnology Inc (UBX) registered a 12.28% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.28% in intraday trading to $1.28, hitting a weekly high. The stock’s 5-day price performance is 23.67%, and it has moved by 13.27% in 30 days. Based on these gigs, the overall price performance for the year is -34.36%. The short interest in Unity Biotechnology Inc (NASDAQ:UBX) is 0.25 million shares and it means that shorts have 3.3 day(s) to cover.
Unity Biotechnology Inc (UBX) estimates and forecasts
Statistics show that Unity Biotechnology Inc has outperformed its competitors in share price, compared to the industry in which it operates. Unity Biotechnology Inc (UBX) shares have gone down -2.29% during the last six months, with a year-to-date growth rate more than the industry average at 45.62% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 36.93%. While earnings are projected to return 49.70% in 2025.
UBX Dividends
Unity Biotechnology Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Unity Biotechnology Inc (NASDAQ:UBX)’s Major holders
Unity Biotechnology Inc insiders own 1.31% of total outstanding shares while institutional holders control 20.55%, with the float percentage being 20.82%.
